REGULATORY UPDATE: CBER Releases 2024 Science Symposium Agenda

The Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) released the agenda for its 2024 Science Symposium, taking place Sept. 16-18 in a hybrid format. This year’s symposium agenda includes several presentations of interest to the blood and biotherapies community.

The “Cell, Tissue and Gene Therapy” section of the symposium will include a keynote address focusing on hematopoietic stem cell gene therapy for inherited blood cell diseases. Additional presentations will explore AAV vectors in gene therapy and immune responses to Cas proteins used in gene editing.

During the “Advanced Manufacturing and Analytics” section, presentations will address novel pathogen reduction technology for plasma and platelets, advanced in vitro systems for enhancing functional assessment of cell therapy products, and use of advanced cell culture systems for immunotherapy testing.

The “Emerging and Re-Emerging Diseases” section will include a presentation focusing on unbiassed metagenomic exploration of transfusion-transmitted infections with nanopore sequencing.

Registration is open to the public.